Mindbio Therapeutics Corp. (MBIO) Stock Statistics & Valuation Metrics
Total Valuation
Mindbio Therapeutics Corp. has a market cap or net worth of CAD 764.72K. The enterprise value is CAD 6.18T.
- Market Cap
- CAD 764.72K
- Enterprise Value
- CAD 6.18T
Share Statistics
Mindbio Therapeutics Corp. has 7,283,063 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 7,283,063
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Mindbio Therapeutics Corp.’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
- Return on Equity (ROE)
- ―
- Return on Assets (ROA)
- ―
- Return on Invested Capital (ROIC)
- ―
- Return on Capital Employed (ROCE)
- ―
- Revenue Per Employee
- ―
- Profits Per Employee
- ―
- Employee Count
- 0
- Asset Turnover
- ―
- Inventory Turnover
- ―
Income Statement
In the last 12 months, Mindbio Therapeutics Corp. had revenue of ― and earned ― in profits. Earnings per share was ―.
- Revenue
- ―
- Gross Profit
- ―
- Operating Income
- ―
- Pretax Income
- ―
- Net Income
- ―
- EBITDA
- -4.25M
- Earnings Per Share (EPS)
- ―
Stock Price Statistics
- Beta
- 3.48
- 52-Week Price Change
- -97.38%
- 50-Day Moving Average
- 0.18
- 200-Day Moving Average
- 0.61
- Relative Strength Index (RSI)
- 22.86
- Average Volume (3m)
- 16.31K
Important Dates
Mindbio Therapeutics Corp. upcoming earnings date is Nov 04, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Jun 01, 2026
- Next Earnings Date
- Nov 04, 2026
- Ex-Dividend Date
- ―
Balance Sheet
Mindbio Therapeutics Corp. has ― in cash and marketable securities with CAD 4.57M in debt, giving a net cash position of ― billion.
- Cash & Marketable Securities
- ―
- Total Debt
- CAD 4.57M
- Net Cash
- ―
- Net Cash Per Share
- ―
- Tangible Book Value Per Share
- ―
Analyst Forecast
The average price target for Mindbio Therapeutics Corp. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -10.54%